Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome
Key facts
- Who runs it
- Thomas Jefferson University
- Where
- Philadelphia and Villanova, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people, planned
- Started
- 4 May 2017
- Ended
- 30 Jun 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- IBS Group
- Healthy Control Group
- Record updated
- 29 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Age greater than 18 years old
- Meets the Rome III criteria for IBS: Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following: 1) Improvement with defecation; 2) Onset associated with a change in frequency of stool; 3) Onset associated with a change in form (appearance) of stool
- Patients have no other pre-existing and active significant gastrointestinal medical, neurological, or psychological disorders as per review by the PI
- Minor, stable health problems that should have no substantial effect on cerebral blood flow will be allowed (i.e. controlled hypertension, medication controlled diabetes) as per review by the PI
- Patients will be allowed to be taking medications or supplements at the initial intake, but they must be on a stable dose regimen for at least 1 month
- Able to give informed consent and willing to complete the study
- No significant current active medical conditions
- Stable medical conditions as determined by the PI are allowed
- No brain or body abnormalities that would affect the acquisition or analysis of the scan
Who cannot take part
- Previous abdominal (bowel) surgery
- Not continuously taking antioxidants or anti-inflammatory medications ( to be reviewed by the PI
- Enrollment in active clinical trial/ experimental therapy within the prior 30 days
- No other active medical conditions potentially requiring changes in treatment regimen during the study duration
- Not pregnant or breast feeding
- Subject is unable or unwilling to lie still in the scanner (i.e. due to claustrophobia or weight > 350 pounds)
- Subject has metal in their body or other reason that they cannot undergo magnetic resonance imaging
Where in United States
- Thomas Jefferson University, Marcus Institute of Integrative Health CentersPhiladelphia, United States
- Thomas Jefferson University, Marcus Institute of Integrative Health CentersVillanova, United States
About the trial
What the trial wants to find out
Although underutilized, what is emerging as one of the best ways of evaluating inflammation in the body, particularly in difficult to observe regions, is through the use of Fluorodeoxyglucose (FDG) positron emission tomography (PET). FDG is taken up in the body much like glucose and is particularly taken up in areas of inflammation where there is increased metabolism. Therefore, this technology can be used to assess inflammation, and measure the reduction in inflammation as the result of integrative interventions that target dietary modifications designed to reduce inflammation. With this proposed study, we plan to use FDG PET-MRI technology to develop a more specific and sensitive approach for evaluating areas of inflammation associated with IBS and measuring improvements in that inflammation in response to effective integrative interventions.
The 2 groups in the trial
- IBS Group
Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
- Healthy Control Group
Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 November 2024